Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MLYCD | O95822 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL162341 | 0.77 | MLYCD (0.46) | GAAALDH1A1MLYCDSMN1; SMN2RIPK1 | |
| SCHEMBL2397439 | 0.73 | GAA (0.57) | GAAALDH1A1HSD11B1EPHX2 | |
| SCHEMBL28261832 | 0.72 | GAA (0.56) | GAAALDH1A1HSD11B1EPHX2 | |
| SCHEMBL23519124 | 0.69 | GAA (0.53) | GAAALDH1A1SMN1; SMN2HSD11B1EPHX2 | |
| SCHEMBL2348011 | 0.69 | EPHX2 (0.51) | GAAALDH1A1KDM4ESMN1; SMN2EPHX2 | |
| SCHEMBL4654242 | 0.69 | MLYCD (0.60) | ALDH1A1MLYCDSMN1; SMN2HPGDEPHX2 | |
| SCHEMBL1619155 | 0.69 | MAPT (0.48) | GAAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL306600 | 0.68 | MLYCD (0.60) | ALDH1A1MLYCDKDM4ESMN1; SMN2HPGD | |
| SCHEMBL11177838 | 0.68 | GAA (0.44) | GAAALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL2396621 | 0.68 | MAOA (0.35) | GAAALDH1A1KDM4ESMN1; SMN2NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013186-B2 | Haloalkyl containing compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20090023781-A1 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors | VIROBAY, INC. (US) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023781-A1 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors | CTSF, CTSS, CTSE | GAA 70/4885ALDH1A1 1944/4885MLYCD 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.